Literature DB >> 16490850

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.

Harry Winfield1, Edward Lain, Thomas Horn, Jerri Hoskyn.   

Abstract

BACKGROUND: Injection site reactions are well recognized in patients treated with etanercept. Previous reports describe histologic findings of a cell-mediated T(H)1 reaction, with CD8+ T cells composing the majority of the dermal infiltrate. OBSERVATIONS: A pruritic, erythematous, edematous patch occurred on the right thigh of a 57-year-old white woman treated for rheumatoid arthritis within 12 to 24 hours after her second dose of subcutaneous etanercept. The patient had a similar reaction to adalimumab injection 2 weeks prior to presentation. While benzyl alcohol is present in the etanercept preparation, and mannitol in both drugs, dermal injection revealed no reaction to these additives. Biopsy specimens from the etanercept injection site demonstrated papillary dermal edema accompanied by a brisk polymorphous infiltrate with a predominance of eosinophils and scattered flame figures.
CONCLUSIONS: Histologic features of eosinophilic cellulitis as a response to etanercept have not been reported to date. Although most injection site reactions contain T cells and represent a T(H)1 immune response, the findings we report suggest a T(H)2-mediated phenomenon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490850     DOI: 10.1001/archderm.142.2.218

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

Review 1.  Eosinophilic Skin Diseases: A Comprehensive Review.

Authors:  Hai Long; Guiying Zhang; Ling Wang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

Review 2.  Hypereosinophilia and seroconversion of rheumatoid arthritis.

Authors:  Rachel K Rosenstein; Richard S Panush; Neil Kramer; Elliot D Rosenstein
Journal:  Clin Rheumatol       Date:  2014-03-08       Impact factor: 2.980

Review 3.  Cutaneous Manifestations of Reactions to Biologics.

Authors:  Iris M Otani; Amy S Levin; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

4.  Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant.

Authors:  Kara Heelan; John F Ryan; Neil H Shear; Conleth A Egan
Journal:  J Dermatol Case Rep       Date:  2013-12-30

5.  Annotation and retrieval of clinically relevant images.

Authors:  Dina Demner-Fushman; Sameer Antani; Matthew Simpson; George R Thoma
Journal:  Int J Med Inform       Date:  2009-07-09       Impact factor: 4.046

Review 6.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

Review 7.  Eosinophilic Drug Allergy.

Authors:  Merin Kuruvilla; David A Khan
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

Review 8.  Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.

Authors:  Christina Kaiser; Ann Knight; Dan Nordström; Tom Pettersson; Jonas Fransson; Ebba Florin-Robertsson; Björn Pilström
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

9.  Recurrent and Diffuse Eczema with Severe Itch and Peripheral Eosinophilia in Healthy Middle Aged Woman.

Authors:  Mahesh Unni; Balachandra Ankad; Varna Naidu; K M Sudakar
Journal:  Indian J Dermatol       Date:  2015 May-Jun       Impact factor: 1.494

10.  Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis.

Authors:  Naoto Azuma; Kiyoshi Matsui; Naoaki Hashimoto; Takahiro Yoshikawa; Hajime Sano
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.